➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Medtronic
Merck
AstraZeneca
McKinsey

Last Updated: January 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Glembatumumab vedotin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Glembatumumab vedotin?

Glembatumumab vedotin is an investigational drug.

There have been 7 clinical trials for Glembatumumab vedotin. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2014.

The most common disease conditions in clinical trials are Melanoma, Triple Negative Breast Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Celldex Therapeutics, National Cancer Institute (NCI), and University of Virginia.

There are eight US patents protecting this investigational drug and sixty-eight international patents.

Recent Clinical Trials for Glembatumumab vedotin
TitleSponsorPhase
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 1/Phase 2
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast CancerCelldex TherapeuticsEarly Phase 1
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast CancerUniversity of VirginiaEarly Phase 1

See all Glembatumumab vedotin clinical trials

Clinical Trial Summary for Glembatumumab vedotin

Top disease conditions for Glembatumumab vedotin
Top clinical trial sponsors for Glembatumumab vedotin

See all Glembatumumab vedotin clinical trials

US Patents for Glembatumumab vedotin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Glembatumumab vedotin   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Glembatumumab vedotin   Start Trial Compositions and methods for treating cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)   Start Trial
Glembatumumab vedotin   Start Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
Glembatumumab vedotin   Start Trial Curcuphenol compounds for increasing MHC-I expression CAVA HEALTHCARE INC. (CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Glembatumumab vedotin

Drugname Country Document Number Estimated Expiration Related US Patent
Glembatumumab vedotin Australia AU2013220749 2032-02-15   Start Trial
Glembatumumab vedotin Brazil BR112014019627 2032-02-15   Start Trial
Glembatumumab vedotin Canada CA2862476 2032-02-15   Start Trial
Glembatumumab vedotin China CN104114705 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Medtronic
Merck
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.